Julia E Head

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational research
    Julia E Head
    Section of Medicine, Institute of Cancer Research, Sutton, UK
    Breast Cancer Res 5:109-12. 2003
  2. ncbi The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo
    Lesley Ann Martin
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London, SW3 6JB United Kingdom
    Mol Cancer Ther 6:2458-67. 2007

Detail Information

Publications2

  1. ncbi 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational research
    Julia E Head
    Section of Medicine, Institute of Cancer Research, Sutton, UK
    Breast Cancer Res 5:109-12. 2003
    ..Presentations on genetic susceptibility and the development of prognostic and predictive markers also created much interest...
  2. ncbi The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo
    Lesley Ann Martin
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London, SW3 6JB United Kingdom
    Mol Cancer Ther 6:2458-67. 2007
    ..Enhanced G1 arrest due to modulation of cell cycle regulatory proteins may be the underlying mechanism for the positive interaction between FTIs and tamoxifen...